{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T13:55:10Z","timestamp":1793282110100,"version":"4.5.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:00:00Z","timestamp":1522281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,24]]},"DOI":"10.1093\/infdis\/jiy176","type":"journal-article","created":{"date-parts":[[2018,3,28]],"date-time":"2018-03-28T11:08:13Z","timestamp":1522235293000},"page":"688-697","source":"Crossref","is-referenced-by-count":81,"title":["HIV-1 Resistance Dynamics in Patients With Virologic Failure to Dolutegravir Maintenance Monotherapy"],"prefix":"10.1093","volume":"218","author":[{"given":"Ingeborg E A","family":"Wijting","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Lungu","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J A","family":"Rijnders","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marchina E","family":"van der Ende","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Infectious Diseases, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanh T","family":"Pham","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada"},{"name":"Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"Mesplede","sequence":"additional","affiliation":[{"name":"McGill University AIDS Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Canada"},{"name":"Department of Microbiology and Immunology, Faculty of Medicine, McGill University, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan D","family":"Pas","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanda J C","family":"Voermans","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"Schuurman","sequence":"additional","affiliation":[{"name":"Division of Virology, Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A M C","family":"van de Vijver","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick H M","family":"Boers","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob A","family":"Gruters","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles A B","family":"Boucher","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J A","family":"van Kampen","sequence":"additional","affiliation":[{"name":"Department of Viroscience, Erasmus MC, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,3,29]]},"reference":[{"key":"key\n\t\t\t\t20180724083916_CIT0001","doi-asserted-by":"crossref","first-page":"e90033","DOI":"10.1172\/jci.insight.90033","article-title":"Quantitative evaluation of the antiretroviral efficacy of dolutegravir","volume":"1","author":"Laskey","year":"2016","journal-title":"JCI Insight"},{"key":"key\n\t\t\t\t20180724083916_CIT0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.virusres.2016.07.006","article-title":"Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance","volume":"239","author":"Brenner","year":"2017","journal-title":"Virus Res"},{"key":"key\n\t\t\t\t20180724083916_CIT0003","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief Report: Dolutegravir Plus Abacavir\/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180724083916_CIT0004","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.7448\/IAS.17.4.19490","article-title":"Once-daily dolutegravir is superior to once-daily darunavir\/ritonavir in treatment-na\u00efve HIV-1-positive individuals: 96 week results from FLAMINGO","volume":"17","author":"Molina","year":"2014","journal-title":"J Int AIDS Soc"},{"key":"key\n\t\t\t\t20180724083916_CIT0005","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"key\n\t\t\t\t20180724083916_CIT0006","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","article-title":"Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study","volume":"382","author":"Cahn","year":"2013","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180724083916_CIT0007","unstructured":"Marcelin AG , GrudeM, CharpentierC, et al French national survey of resistance to integrase inhibitors shows high differences of resistance selection rate in case of virological failure in a context of routine hospital care (ANRS-AC11 Virology Network) [abstract O332]. Presented at: International Congress of Drug Therapy in HIV Infection, Glasgow, Scotland, 23\u201326 2016."},{"key":"key\n\t\t\t\t20180724083916_CIT0008","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/infdis\/jir636","article-title":"Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S\/GSK1349572) using clonal viral variants selected in patients failing raltegravir","volume":"204","author":"Canducci","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180724083916_CIT0009","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/AAC.01209-10","article-title":"In Vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor","volume":"55","author":"Kobayashi","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180724083916_CIT0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jviromet.2016.10.002","article-title":"Development of a phenotypic susceptibility assay for HIV-1 integrase inhibitors","volume":"238","author":"Heger","year":"2016","journal-title":"J Virol Methods"},{"key":"key\n\t\t\t\t20180724083916_CIT0011","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/infdis\/jis750","article-title":"Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study","volume":"207","author":"Eron","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180724083916_CIT0012","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/jac\/dkw011","article-title":"Dolutegravir as maintenance monotherapy: first experiences in HIV-1 patients","volume":"71","author":"Rokx","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724083916_CIT0013","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1093\/jac\/dkw186","article-title":"Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia","volume":"71","author":"Katlama","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724083916_CIT0014","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1093\/jac\/dkw078","article-title":"Dolutegravir monotherapy in HIV-infected patients with sustained viral suppression","volume":"71","author":"Rojas","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724083916_CIT0015","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3851\/IMP3082","article-title":"Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: DoluMono cohort results","volume":"22","author":"Oldenbuettel","year":"2017","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180724083916_CIT0016","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jac\/dkv430","article-title":"Dolutegravir-based monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients","volume":"71","author":"Gubavu","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724083916_CIT0017","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(17)30152-2","article-title":"Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomized non-inferiority trail","author":"Wijting","year":"2017","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180724083916_CIT0018","doi-asserted-by":"crossref","first-page":"31186","DOI":"10.1074\/jbc.M704935200","article-title":"Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors","volume":"282","author":"Dicker","year":"2007","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20180724083916_CIT0019","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00922-17","article-title":"Mutations located outside the integrase gene can confer resistance to HIV-1 integrase strand transfer inhibitors","author":"Malet","year":"2017","journal-title":"MBio"},{"key":"key\n\t\t\t\t20180724083916_CIT0020","author":"Stanford University"},{"key":"key\n\t\t\t\t20180724083916_CIT0021"},{"key":"key\n\t\t\t\t20180724083916_CIT0022","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/hiv.12386","article-title":"Week 96 efficacy and safety of darunavir\/ritonavir monotherapy vs. darunavir\/ritonavir with two nucleoside reverse transcriptase inhibitors in the PROTEA trial","volume":"18","author":"Girard","year":"2017","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20180724083916_CIT0023","unstructured":"Blanco JL , OldenbuettelC, ThomasR, et al Pathways of resistance in subjects failing dolutegravir monotherapy [abstract 42]. Presented at: 2017 Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, 13\u201316 February 2017. http:\/\/www.croiconference.org\/sessions\/pathways-resistance-subjects-failing-dolutegravir-monotherapy. Accessed 26 April 2017."},{"key":"key\n\t\t\t\t20180724083916_CIT0024","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","article-title":"Emergent drug resistance with integrase strand transfer inhibitor-based regimens","volume":"31","author":"Lepik","year":"2017","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180724083916_CIT0025","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3851\/IMP2878","article-title":"Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study","volume":"20","author":"Akil","year":"2015","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180724083916_CIT0026","unstructured":"Underwood M , DeAndaF, DoreyD, et al Resistance post week 48 in ART-experienced, integrase inhibitor-na\u00efve subjects with dolutegravir (DTG) vs. raltegravir (RAL) in SAILING (ING111762) [abstract 6]. Presented at: 13th European Workshop on HIV and Hepatitis: Treatment Strategies and Antiviral Drug Resistance, Barcelona, Spain, 3\u20135 June 2015."},{"key":"key\n\t\t\t\t20180724083916_CIT0027","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1093\/jac\/dkx195","article-title":"Monotherapy with either dolutegravir or raltegravir fails to durably suppress HIV viraemia in humanized mice","volume":"72","author":"Heredia","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724083916_CIT0028","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S2055-6640(20)31150-X","article-title":"HIV-1 resistance to dolutegravir: update and new insights","volume":"1","author":"Wainberg","year":"2015","journal-title":"J Virus Erad"},{"key":"key\n\t\t\t\t20180724083916_CIT0029","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/QAI.0b013e31826bfd02","article-title":"The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults","volume":"61","author":"Underwood","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20180724083916_CIT0030","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1093\/infdis\/jiy175","article-title":"The S230R integrase substitution associated with viral rebound during DTG monotherapy confers low levels INSTI drug resistance","volume":"218","author":"Pham","year":"2018","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20180724083916_CIT0031","first-page":"17","article-title":"Characterization and structural analysis of HIV-1 integrase conservation","volume":"11","author":"Ceccherini-Silberstein","year":"2009","journal-title":"AIDS Rev"},{"key":"key\n\t\t\t\t20180724083916_CIT0032","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dkq326","article-title":"Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors","volume":"65","author":"Ceccherini-Silberstein","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180724083916_CIT0033","doi-asserted-by":"crossref","first-page":"e00315\u20137","DOI":"10.1128\/AAC.00315-17","article-title":"Impact of HIV-1 integrase L74F and V75I mutations in a clinical isolate on resistance to second-generation integrase strand transfer inhibitors","volume":"61","author":"Hachiya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180724083916_CIT0034","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.biocel.2004.02.016","article-title":"\u2018Binding, bending and bonding\u2019: polypurine tract-primed initiation of plus-strand DNA synthesis in human immunodeficiency virus","volume":"36","author":"Rausch","year":"2004","journal-title":"Int J Biochem Cell Biol"},{"key":"key\n\t\t\t\t20180724083916_CIT0035","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1742-4690-7-44","article-title":"Expression of Nef from unintegrated HIV-1 DNA downregulates cell surface CXCR4 and CCR5 on T-lymphocytes","volume":"7","author":"Sloan","year":"2010","journal-title":"Retrovirology"},{"key":"key\n\t\t\t\t20180724083916_CIT0036","doi-asserted-by":"crossref","first-page":"17358","DOI":"10.1074\/jbc.274.24.17358","article-title":"Multiple integrase functions are required to form the native structure of the human immunodeficiency virus type I intasome","volume":"274","author":"Chen","year":"1999","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20180724083916_CIT0037","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/v1030713","article-title":"HIV-1 integrase-DNA recognition mechanisms","volume":"1","author":"Kessl","year":"2009","journal-title":"Viruses"},{"key":"key\n\t\t\t\t20180724083916_CIT0038","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.1016\/S0021-9258(18)53242-7","article-title":"The sequence features important for plus strand priming by human immunodeficiency virus type 1 reverse transcriptase","volume":"268","author":"Pullen","year":"1993","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20180724083916_CIT0039","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1128\/JVI.70.8.5288-5296.1996","article-title":"Sequence and structural determinants required for priming of plus-strand DNA synthesis by the human immunodeficiency virus type 1 polypurine tract","volume":"70","author":"Powell","year":"1996","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180724083916_CIT0040","doi-asserted-by":"crossref","first-page":"13315","DOI":"10.1128\/JVI.78.23.13315-13324.2004","article-title":"Effects of mutations in the G tract of the human immunodeficiency virus type 1 polypurine tract on virus replication and RNase H cleavage","volume":"78","author":"Julias","year":"2004","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20180724083916_CIT0041","doi-asserted-by":"crossref","first-page":"16725","DOI":"10.1073\/pnas.0804192105","article-title":"HIV rebounds from latently infected cells, rather than from continuing low-level replication","volume":"105","author":"Joos","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20180724083916_CIT0042","doi-asserted-by":"crossref","first-page":"e1005000","DOI":"10.1371\/journal.ppat.1005000","article-title":"HIV reactivation from latency after treatment interruption occurs on average every 5-8 days\u2013implications for HIV remission","volume":"11","author":"Pinkevych","year":"2015","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t20180724083916_CIT0043","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1097\/QAD.0b013e32833032d4","article-title":"Factors influencing peripheral blood mononuclear cell-associated HIV-1 DNA level after long-term suppressive antiretroviral therapy in 236 patients","volume":"23","author":"Burgard","year":"2009","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180724083916_CIT0044","first-page":"33","article-title":"Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure","volume":"1","author":"de Jong","year":"1996","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180724083916_CIT0045","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2334-13-52","article-title":"Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencing","volume":"13","author":"Bansode","year":"2013","journal-title":"BMC Infect Dis"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/218\/5\/688\/25206918\/jiy176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T05:57:05Z","timestamp":1660715825000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/218\/5\/688\/4956224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,29]]},"references-count":45,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,3,29]]},"published-print":{"date-parts":[[2018,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiy176","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,9,1]]},"published":{"date-parts":[[2018,3,29]]}}}